Tolerability and patient compliance.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanism-based pharmacological reasoning with no systematic search methodology or original clinical trial data reported.
What was done
This narrative review describes how differences in receptor interactions among antidepressants (particularly newer agents like SSRIs and mirtazapine compared to tricyclic compounds) influence tolerability, adverse effect profiles, and patient compliance.
What was found
No numerical data, statistics, or sample sizes are reported in the abstract. Qualitatively, newer antidepressants demonstrate improved tolerability, cardiac safety, and safety in overdose compared to tricyclics. Mirtazapine's H1 blockade is linked to transient somnolence and weight gain, its 5-HT2 blockade to absent sexual dysfunction and agitation, and its 5-HT3 blockade to an absence of gastrointestinal side effects.
Why it matters
Recognizing specific receptor-mediated adverse effect profiles allows clinicians to match antidepressant selection to individual patient tolerability concerns, potentially improving treatment adherence.
Limits
The abstract provides no empirical quantitative data, effect estimates, or systematic review methodology. Conclusions reflect narrative pharmacological reasoning rather than direct clinical trial evidence.
Cited by
- context Side effects from SSRIs, such as sexual dysfunction and anhedonia, are caused by the drugs interacting across many different serotonin receptor subtypes.